Results 281 to 290 of about 180,550 (320)

Revisorerklæringer: Revisors, hvervgivers og erklæringsmodtagers kendskab hertil [PDF]

open access: yes, 2006
Nielsen, Anita Bøgelund   +1 more
core  

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

open access: yesArthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti   +19 more
wiley   +1 more source

Vida [PDF]

open access: yes, 1920
Cavallé, Pere
core  

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

open access: yesArthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner   +14 more
wiley   +1 more source

The role of cystatin C in kidney injury in children and adolescents with type 1 diabetes mellitus: a systematic review. [PDF]

open access: yesJ Bras Nefrol
Gkiourtzis N   +11 more
europepmc   +1 more source

Revisores 2000

open access: yesActas Dermo-Sifiliográficas, 2001
openaire   +1 more source

Home - About - Disclaimer - Privacy